

Curriculum vitae

Name	Andreas Kerschbaumer
Address	Medical University of Vienna, Department of Medicine III, Division of Rheumatology Währinger Gürtel 18-20, 1090, Vienna, Austria
E-mail	andreas.kerschbaumer@meduniwien.ac.at
DOB	18.01.1990
Citizenship	Austria

Education

03/2018 – 10/2024	Residency and fellowship in internal medicine & rheumatology (ÄAO2015)
10/2016 – 09/2023	Doctoral/PhD program (N094), Medical University of Vienna PhD Thesis: <i>“Discovering Influencing Factors on Efficacy Outcomes in Inflammatory Arthritis Clinical Trials”</i>
10/2010 – 10/2016	Study of medicine (N202), Medical University of Vienna MD Thesis: <i>“Serum Complement C3 as a Possible Disease Activity Marker in Psoriatic Arthritis”</i>

Work experience

10/2024 – today	Attending physician in rheumatology <i>Medical University of Vienna, Department of Medicine III, Division of Rheumatology.</i>
03/2018 – 09/2024	Residency: Internal medicine, Fellowship: internal medicine & rheumatology (ÄAO2015) <i>Medical University of Vienna, clinical rotations: nephrology, infectious diseases, bone marrow transplantation unit, emergency medicine, rheumatology.</i>
10/2016 – 02/2018	Research / PhD studies <i>MUV – Vienna General Hospital, Department of Medicine III, Rheumatology</i> Clinical science (outcomes research, systematic literature reviews, meta-analyses), database development and -management, sub-investigator in clinical trials

Taskforces / Memberships

03/24 – today	EULAR Recommended Methodologist in Training
11/24 – today	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2025 update – Co-Methodologist
06/23 – 11/24	Consensus statement: Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors: 2024 Update – Methodologist
11/22 – 03/24	EULAR Taskforce: EULAR Recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 Update – Fellow
2000 – 2023	Taskforce on development of treat to target (T2T) recommendations for giant cell arteritis and polymyalgia rheumatica – Co-Methodologist
2018 – 2023	The Rheumatology Education Group (TREG) – International faculty
2021 – 2022	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update – Fellow, SLR on treatment efficacy
2020 – 2022	Taskforce on the consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions – Co-Methodologist
2019 – 2021	EULAR Taskforce: Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis – Co-Methodologist
2018 – 2019	Consensus statement: Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors – Fellow
2018 – 2019	EULAR Taskforce: EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update – Fellow
2018 – 2019	EULAR Taskforce: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update – Fellow, SLR on treatment efficacy

Awards

11/2024	Emerging Investigator Excellence Award at ACR convergence 2024 for the Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes category, Abstract: “Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis” - American College of Rheumatology
01/2024	Thesis award 2023 - Verein zur Förderung von Wissenschaft und Forschung (VFWF)
11/2023	Thesis award 2023 - Austrian rheumatologic society (ÖGR)
11/2023	Publication award - Austrian rheumatologic society (ÖGR) – „Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis”
12/2021	1st place of the Theodor-Billroth-Price - Austrian Doctors Chamber of Vienna – „Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology“
11/2022	Publication award - Austrian rheumatologic society (ÖGR) – "Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis"
01/2021	Researcher of the month (Medical University of Vienna)
11/2020	Austrian rheumatologic society: Case of the year 2020 – “Generalized pustulosis after holiday at the seaside in Africa”
12/2016	Publication award - Austrian rheumatologic society (ÖGR) – „The effects of structural damage on functional disability in psoriatic arthritis”

Publications (selection)

- Kerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. **Ann Rheum Dis**. Published Online First: 19 March 2024. doi: 10.1136/ard-2024-225534
- Hysa E, Bond M, Ehlers L, Camellino D, Falzon L, Dejaco C, Buttgereit F, Aletaha D, Kerschbaumer A. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review. **Rheumatology (Oxford)**. 2024 Feb 1;63(2):285-297. doi: 10.1093/rheumatology/kead471.
- Konzett V & Kerschbaumer A, Smolen JS, Aletaha D. Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis. **Ann Rheum Dis**. 2024 Jan 2;83(1):58-64. doi: 10.1136/ard-2023-224477. PMID: 37758287.
- Kerschbaumer A, Stimakovits NM, Smolen JS, Stefanova T, Chwala E, Aletaha D. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis. **Ann Rheum Dis**. 2023 Jan 10;ard-2022-223349. doi: 10.1136/ard-2022-223349. Epub ahead of print. PMID: 36627167.
- Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. **Ann Rheum Dis**. 2022 Nov 11;ard-2022-223365. doi: 10.1136/ard-2022-223365. Epub ahead of print.
- Kerschbaumer A, Rivai ZI, Smolen JS, et al. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. **Ann Rheum Dis**. 2022 Jun 20;annrheumdis-2021-221807. doi: 10.1136/annrheumdis-2021-221807.
- Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. **RMD OPEN** 2020;6. doi:10.1136/rmdopen-2020-001374
- Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological Treatment of Psoriatic Arthritis: A Systematic Literature Research for the 2019 Update of the EULAR Recommendations for the Management of Psoriatic Arthritis. **Ann Rheum Dis**. 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163.
- Kerschbaumer A, Smolen JS, Herkner H, et al. Efficacy Outcomes in Phase 2 and Phase 3 Randomized Controlled Trials in Rheumatology. **Nature Medicine**. 2020 Apr 20. doi: 10.1038/s41591-020-0833-4.
- Kerschbaumer A, Aletaha D. Targeting p19 in Psoriatic Arthritis: More Than Just Another Therapeutic Approach? **Lancet**. 2020 Apr 4;395(10230):1091-1093. doi: 10.1016/S0140-6736(20)30525-0 (Letter).
- Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. **Ann Rheum Dis**. Published Online First: 07 February 2020. doi: 10.1136/annrheumdis-2019-216656
- Aletaha D, Kerschbaumer A, Smolen JS. Tofacitinib for Psoriatic Arthritis. **New England Journal of Medicine**. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189 (Letter).
- Kerschbaumer A, Baker D, Smolen JS, Aletaha D. The effects of structural damage on functional disability in psoriatic arthritis. **Ann Rheum Dis**. 2017 Dec;76(12):2038–2045.